Titlebook: Bioinformatics and Drug Discovery; Richard S. Larson,Tudor I. Oprea Book 2019Latest edition Springer Science+Business Media, LLC, part of

只看該作者 · 發(fā)表于 2025-3-25 08:15:37

,Theorie der r?umlichen Kerbwirkung,. Similar to data set preprocessing in other fields, there is an initial need to complete data quality evaluation; however, with large heterogeneous clinical data sets, it is important to standardize the data in order to facilitate dimensionality reduction. This is particularly important for clinica

只看該作者 · 發(fā)表于 2025-3-25 12:55:41

https://doi.org/10.1007/978-3-642-53069-2ges in gene expression and signal transduction. L1000 big datasets provide gene expression profiles induced by over 10,000 compounds, shRNAs, and kinase inhibitors using L1000 platform. We developed a systematic compound signature discovery pipeline named csNMF, which covers from raw L1000 data proc

只看該作者 · 發(fā)表于 2025-3-25 17:05:02

High-Throughput Screening for Drug Combinationsed drugs using a full dose-response matrix scheme using viability as the readout. We provide details of the automation required to run the screen and the informatics required to process data from screening robot and subsequent analysis and visualization of the datasets.

只看該作者 · 發(fā)表于 2025-3-25 20:04:11

Post-processing of Large Bioactivity Datathe processing of large bioactivity data and methods for handling these issues in a post-processing scenario. Specifically described are observations from a recent effort (Harris, ., 2017) to post-process massive amounts of bioactivity data from the NIH’s PubChem Bioassay repository (Wang et al., Nucleic Acids Res 42:1075–1082, 2014).

只看該作者 · 發(fā)表于 2025-3-26 00:38:19

Isomeric and Conformational Analysis of Small Drug and Drug-Like Molecules by Ion Mobility-Mass Specs are highlighted and placed in the context of both a separation and characterization perspective. We conclude this chapter with a guided reference protocol for obtaining routine IM-MS spectra on a commercially available uniform-field IM-MS.

只看該作者 · 發(fā)表于 2025-3-26 04:20:26

只看該作者 · 發(fā)表于 2025-3-26 10:10:40

Drug Signature Detection Based on L1000 Genomic and Proteomic Big Dataessing to drug screening and mechanism generation. The discovered compound signatures of breast cancer were consistent with the LINCS KINOMEscan data and were clinically relevant. In this way, the potential mechanisms of compounds’ efficacy are elucidated by our computational model.

只看該作者 · 發(fā)表于 2025-3-26 14:18:21

只看該作者 · 發(fā)表于 2025-3-26 19:20:30

Die Formzahldiagramme und ihre Handhabung,zed by computationally ranking the closeness between a disease network and a drug’s signaling network. Furthermore, we describe the use of the most perturbed HLA genes to assess the safety risk for immune-mediated adverse reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis.

		自動登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點評	投稿經(jīng)驗總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 14:26
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved